Maze Therapeutics, Inc. 8-K

What Happened
Maze Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026. The company issued a press release on May 12, 2026 reporting those quarterly results; the full press release is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: May 12, 2026 (Current Report on Form 8-K).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Disclosure format: Press release announcing financial results included as Exhibit 99.1; Cover Page Interactive Data File (Inline XBRL) included as Exhibit 104.
• Report signed by Courtney Phillips, General Counsel and Corporate Secretary.

Why It Matters
This 8-K provides Maze’s official quarterly results disclosure (earnings/financial condition) for Q1 2026. Retail investors should review the furnished press release (Exhibit 99.1) for specific figures—revenue, expense, cash position, and any forward-looking commentary—that can affect valuation and near-term outlook. Because the 8-K itself references the press release rather than restating numbers, consult the Exhibit and subsequent filings (e.g., the next 10-Q) for full financial detail and official reconciliations.